In 2004, the FDA sponsored a study on occurrences of rhabdomyolysis, a sometimes deadly side effect of cholesterol-lowering statins, generally believed to be rare after the withdrawal of cerivastatin. The FDA study looked at patients using statins for a period of one year, with results showing that only 0.44 in 10,000 patients will develop this sometimes life-threatening condition. The creators of eHealthMe.
This entry was posted
on Sunday, September 7th, 2008 at 8:00 am and is filed under Cholesterol.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
